Iris Kersten

Nijmegen, GE 6525GA, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease.

Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease.

Journal: EBioMedicine

Published: January 22, 2026

Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.

Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.

Journal: Acta neuropathologica communications

Published: April 19, 2024

Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy.

Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy.

Journal: Alzheimer's research & therapy

Published: December 21, 2023

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Journal: Journal of neurochemistry

Published: October 25, 2023

Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients.

Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients.

Journal: Acta neuropathologica communications

Published: October 13, 2023

Divergent Associations of Slow-Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid-Beta.

Divergent Associations of Slow-Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid-Beta.

Journal: Annals of neurology

Published: September 06, 2023

Correction: Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.

Correction: Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.

Journal: Annals of neurology

Published: June 09, 2023

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD

Published: February 13, 2023

Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.

Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.

Journal: Alzheimer's research & therapy

Published: December 16, 2022

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.

Journal: Alzheimer's research & therapy

Published: November 25, 2022

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.

Journal: Annals of neurology

Published: August 01, 2022

Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy.

Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy.

Journal: Neuropathology and applied neurobiology

Published: December 03, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026